When tested on two groups of mice with sepsis — one group with CD39 and the other group missing the enzyme — the CD39 was able to clear the dangerous buildup of adenosine triphosphate from the bloodstream, significantly improving the survival rate of the septic mice with the enzyme.
Additionally, the CD39 enzyme decreased inflammation, organ damage, immune cell apoptosis and bacterial load in the mice, indicating its potential use in other diseases associated with inflammation, including trauma, hemorrhagic shock and burns.
More articles on sepsis:
MEDITECH embeds sepsis alerts into EHR workflow
Midwives in Texas may see stricter infection control standards for water births
How Dartmouth-Hitchcock cut sepsis mortality in half
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
